WEST LAFAYETTE, Ind. – Kylin Therapeutics, Inc., a developer of next-generation RNAi therapeutics, announced the expansion of its research and development efforts. The project will advance promising new RNAi cancer therapies. This expanded effort will be conducted at Purdue University’s Bindley Bioscience Center, and will focus on further validating targeted, systemically delivered cancer therapies utilizing Kylin’s proprietary pRNAi platform. “Our in vivo efforts have shown pRNAi to be a very potent and versatile RNAi inducing platform,” said Eric Davis, the president and CEO of Kylin. “This expanded effort will enable us to test the flexibility of the pRNAi platform against various cancer targets.”

About Kylin Therapeutics, Inc.

Kylin Therapeutics, Inc. is a biotechnology company focused on the development of a novel platform technology called pRNA. pRNA is a discrete, RNA-based nanoparticle system. Kylin has re-engineered pRNA to induce RNA interference (RNAi). The resulting therapeutic platform is called pRNAi. This platform represents the next generation of RNAi-inducing therapeutics with superior pharmacokinetics and potency over siRNA. President and CEO Eric Davis may be contacted at (765) 412-6661 or by email at edavis@kylintherapeutics.com. More information regarding Kylin Therapeutics may be found at www.kylintherapeutics.com.